The CGRP Revolution: The Molecule That Changed Everything

The Borrowed Medicine Problem

Your doctor hands you a prescription. It’s a blood pressure pill. You don’t have high blood pressure. But you do have migraine — and this is the best medicine can offer.

For most of the 20th century, every preventive drug prescribed for migraine was designed for something else. Beta-blockers built for hypertension. Anticonvulsants developed for epilepsy. Antidepressants intended for mood disorders.^[1] Sometimes they helped. Often the side effects were devastating: weight gain, cognitive fog, tingling in the extremities, crushing fatigue. In the United States, nearly 30% of patients abandoned their preventive medication within six months — not because their migraines improved, but because the cure felt worse than the disease.^[2]

Migraine deserved better. It affects over 1 billion people worldwide — roughly 14% of the global population — and ranks as the second leading cause of years lived with disability on the planet.^{[3, 4]} Among young women, it ranks first.^[5] This is not a minor inconvenience. It is a neurological condition that steals careers, fractures relationships, and erases entire days from the calendar.

Yet for decades, researchers had no clear molecular target. They knew the pain was real. They simply didn’t know which molecule to chase.

Then they found CGRP. And everything changed.

A Peptide Hiding in Plain Sight

The CGRP story begins not in a headache clinic but in a genetics lab. In 1982, Susan Amara and colleagues at the University of California discovered something unexpected: the calcitonin gene — responsible for calcium regulation — could be spliced differently in nerve tissue, producing an entirely new peptide.^[6] A year later, Michael Rosenfeld’s team confirmed and named it: calcitonin gene-related peptide, or CGRP.^[7] Thirty-seven amino acids long. One of the most potent vasodilators (substances that widen blood vessels) ever found. Packed into sensory neurons throughout the nervous system.

Nobody connected it to migraine. Not yet.

That connection required two scientists, a Swedish conference hall, and a conversation over coffee.

The Coffee That Changed Neurology

June 1985. Peter Goadsby — a young Australian medical student obsessed with migraine — sat in the audience at a conference in Lund, Sweden. On stage, Lars Edvinsson, a physician at the local university hospital, was describing the trigeminovascular system: the network of nerves wrapped around blood vessels in the head. Edvinsson had been mapping the neuropeptides in these nerve fibers for years. He’d found that trigeminal neurons contained CGRP — and that the peptide could dilate cerebral blood vessels.^[8]

After the talk, Goadsby introduced himself. They talked. They realized they were asking the same question from different angles: could CGRP be the chemical signature of a migraine attack?

That coffee launched a partnership that would reshape the field.

The Smoking Gun

By the late 1980s, Edvinsson and Goadsby had developed the methodology to measure neuropeptides directly in the human cranial circulation. The pivotal experiment came in 1990. They drew blood from the jugular vein of patients in the grip of a severe migraine attack, then again after the pain resolved.^[9]

The results were unambiguous. CGRP levels surged during the attack and dropped back to normal when it ended. No other neuropeptide showed this pattern as clearly. Substance P, neurokinin A — the other suspects — were ruled out. CGRP was the signal.

Three years later, they tightened the case. Sumatriptan — a new triptan drug at the time — reduced CGRP levels in the jugular blood at the same time it relieved the headache.^[10] When CGRP went down, the migraine went away.

But correlation is not causation. The final, definitive piece came in 2002 from Jes Olesen’s group in Copenhagen. They injected CGRP intravenously into people susceptible to migraine.^[11] Every patient developed a headache. Three of nine met full diagnostic criteria for migraine. When the same injection was given to people without migraine, only a mild headache resulted.

Proof of Concept — and a Roadblock

Identifying a target is one thing. Building a drug to block it is another. And the road from CGRP discovery to CGRP therapy was not straight.

The first attempt came in 2004, when Olesen, Goadsby, and an international team tested olcegepant (BIBN 4096 BS), a small molecule designed to block the CGRP receptor.^[12] Administered intravenously to patients during a migraine attack, it achieved a 66% response rate at 2 hours — compared to 27% for placebo. The study was published in the New England Journal of Medicine. The scientific community took notice: blocking CGRP could treat migraine.

But olcegepant couldn’t be taken as a pill. Its molecular structure made oral delivery impossible, and intravenous infusions are impractical for a condition that strikes without warning.

The next generation of small-molecule CGRP blockers — called gepants — solved the oral problem but created a new one. Telcagepant showed efficacy in clinical trials, then caused liver toxicity in some patients during prevention studies.^[13] Development was halted. Other first-generation gepants met similar fates by 2010.

The Antibody Breakthrough

That approach came from monoclonal antibodies — lab-engineered proteins designed to neutralize a specific target with extraordinary precision. Unlike a gepant, which blocks the CGRP receptor for hours, a monoclonal antibody binds to CGRP or its receptor and stays active for weeks. One injection. Once a month. Sometimes once every three months.

Four antibodies were developed for migraine prevention: erenumab (which targets the CGRP receptor), and fremanezumab, galcanezumab, and eptinezumab (which target the CGRP molecule itself).^[14]

The clinical trial results broke new ground.

In the landmark STRIVE trial — published in the New England Journal of Medicine in 2017 — 955 patients with episodic migraine received either erenumab or placebo for six months.^[15] Patients on the higher dose (140 mg) experienced a 3.7-day reduction in monthly migraine days from a baseline of 8.3. Half of them had their migraine days cut by at least 50% — nearly three times the odds compared to placebo. Over 90% of patients completed the study. Adverse events were comparable to placebo: no brain fog, no weight gain, no cognitive dulling.

In May 2018, erenumab became the first FDA-approved treatment specifically built for migraine prevention.^[16] Within a year, all four monoclonal antibodies had received regulatory approval.

Head-to-Head: The Definitive Comparison

A drug that beats placebo is promising. A drug that beats the standard of care is transformative.

In 2022, the HER-MES trial delivered that proof.^[17] This Phase 4 study — the first head-to-head comparison of a CGRP antibody against a standard-of-care migraine preventive — randomized 777 patients to receive either erenumab or topiramate for 24 weeks.

The gap was enormous. In the topiramate group, 38.9% of patients quit due to side effects — paresthesia, attention problems, fatigue, nausea. In the erenumab group, just 10.6% did. And 55.4% of erenumab patients achieved at least a 50% reduction in monthly migraine days, compared to 31.2% on topiramate.^[17]

Long-term data extending to 5 years confirmed the durability. Patients on erenumab maintained an average 62% reduction in migraine days, with no new safety signals emerging over the entire follow-up period.^[18]

The Gepants Return

While the antibodies were transforming prevention, the gepant story was far from over. A second generation of oral CGRP receptor antagonists — ubrogepant, rimegepant, and atogepant — overcame the liver safety issues that sank their predecessors.^[19] These newer molecules showed no significant hepatotoxicity and proved effective for both acute treatment and prevention of migraine.

Rimegepant holds a unique position: it is the only medication currently approved by the FDA for both treating a migraine attack and preventing future ones.^[20] This dual capability bridges a divide that has existed since the beginning of migraine pharmacology — the artificial wall between what you take during an attack and what you take to stop the next one.

As of 2026, eight CGRP-targeting therapies carry FDA approval: four monoclonal antibodies and four gepants.^[21] Together, they represent the largest class of migraine-specific treatments ever developed.

First-Line: A Historic Shift

In March 2024, the American Headache Society took a step that would have been unthinkable a decade earlier. It officially recommended CGRP-targeting therapies as a first-line option for migraine prevention — alongside, not after, traditional treatments.^[22]

The old model required patients to try and fail two or more older medications before gaining access to CGRP therapies. The new position eliminated that requirement. The AHS noted that the cumulative evidence supporting these drugs — in volume, scope, and quality — “significantly exceeds that for any other preventive treatment approach.”^[22] More than 150 real-world studies published in just two years corroborated the clinical trial data: effective, well tolerated, safe over the long term.

What This Means for You

If your current preventive treatment isn’t working — or if the side effects are stealing the quality of life the medication was supposed to protect — CGRP-targeting therapies may be worth discussing with your doctor. Under current AHS guidelines, you do not need to “fail” older medications first.^[22]

These treatments are available as monthly or quarterly injections (monoclonal antibodies) or as daily or as-needed oral tablets (gepants). They work for both episodic and chronic migraine. They have been studied in patients who failed multiple prior preventives — and still showed meaningful benefit.^[23]

The CGRP story is one of the great bench-to-bedside success stories in modern neuroscience. It took 40 years — from Amara’s gene-splicing discovery in 1982, through Edvinsson and Goadsby’s blood samples in 1990, past Olesen’s provocation experiments in 2002, through the clinical trials, the setbacks, the second chances — to arrive where we are today.

For the first time in the history of migraine, we have an entire class of drugs designed specifically for the disease. Not borrowed. Not repurposed. Built.